These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30151212)

  • 1. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
    Brown K; Mendell J; Ohwada S; Hsu C; He L; Warren V; Dishy V; Zahir H
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00418. PubMed ID: 30151212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
    Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
    Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
    Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
    Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
    J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
    Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S
    Medicine (Baltimore); 2020 Sep; 99(36):e21976. PubMed ID: 32899037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
    Tachibana M; Yamamura N; Atiee GJ; Hsu C; Warren V; He L; Dishy V; Zahir H
    Br J Clin Pharmacol; 2018 Oct; 84(10):2317-2324. PubMed ID: 29920736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
    Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
    J Diabetes Investig; 2019 Sep; 10(5):1299-1306. PubMed ID: 30672128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
    van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
    J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.
    McColm J; Brittain C; Suriyapperuma S; Swanson S; Tauscher-Wisniewski S; Foster J; Soon D; Jackson K
    Br J Clin Pharmacol; 2017 Aug; 83(8):1654-1667. PubMed ID: 28156011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
    Jansen M; Mendell J; Currie A; Dow J; He L; Merante D; Dishy V; Ishizuka H; Zahir H
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):597-612. PubMed ID: 29870596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
    Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
    Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.